pemetrexed pfizer (previously known as pemetrexed hospira uk limited)
pfizer europe ma eeig - pemetrexed ditromethamine - carcinoma, non-small-cell lung; mesothelioma - folic acid analogues, antimetabolites - malignant pleural mesotheliomapemetrexed hospira uk limited in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.non-small cell lung cancerpemetrexed hospira uk limited in combination with cisplatin is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see smpc section 5.1).pemetrexed hospira uk limited is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see smpc section 5.1).pemetrexed hospira uk limited is indicated as monotherapy for the second-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see smpc section 5.1).
taro-pemetrexed powder for solution
taro pharmaceuticals inc - pemetrexed (pemetrexed disodium) - powder for solution - 100mg - pemetrexed (pemetrexed disodium) 100mg - antineoplastic agents
taro-pemetrexed powder for solution
taro pharmaceuticals inc - pemetrexed (pemetrexed disodium) - powder for solution - 500mg - pemetrexed (pemetrexed disodium) 500mg - antineoplastic agents
taro-pemetrexed powder for solution
taro pharmaceuticals inc - pemetrexed (pemetrexed disodium) - powder for solution - 1000mg - pemetrexed (pemetrexed disodium) 1000mg - antineoplastic agents
pemetrexed sandoz pemetrexed (as disodium) 500mg powder for injection vial
sandoz pty ltd - pemetrexed disodium -
pemetrexed-drla pemetrexed (as disodium) 100 mg powder for injection vial
dr reddys laboratories australia pty ltd - pemetrexed disodium -
pemetrexed taro 100 mg
taro international ltd, israel - pemetrexed - powder for concentrate for solution for infusion - pemetrexed 100 mg/vial - pemetrexed - 1.pemetrexed taro in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curatible surgery. 2.pemetrexed taro in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. 3.pemetrexed taro is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.4.pemetrexed taro is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.
pemetrexed taro 1000 mg
taro international ltd, israel - pemetrexed - powder for concentrate for solution for infusion - pemetrexed 1000 mg/vial - pemetrexed - 1.pemetrexed taro in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curatible surgery. 2.pemetrexed taro in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. 3.pemetrexed taro is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.4.pemetrexed taro is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.
pemetrexed taro 500 mg
taro international ltd, israel - pemetrexed - powder for concentrate for solution for infusion - pemetrexed 500 mg/vial - pemetrexed - 1.pemetrexed taro in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curatible surgery. 2.pemetrexed taro in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. 3.pemetrexed taro is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.4.pemetrexed taro is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.
pemetrexed teva 100 mg
abic marketing ltd, israel - pemetrexed - powder for concentrate for solution for infusion - pemetrexed 100 mg - pemetrexed - malignant pleural mesothelioma :pemetrexed teva in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curatible surgery. non-small cell lung cancer: pemetrexed teva in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed teva is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy. pemetrexed teva is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.